Patent intelligence · US
US 11161906
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
Patent details — US 11161906
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 2, 2021
- Expiration
- Oct 28, 2041
- Applicant
- CytomX Therapeutics, Inc.
- Claims
- 45
- CPC classes
- A61P, A61P35/00
Quick answer
US 11161906 (Multispecific antibodies, multispecific activatable antibodies and methods of using the same) is held by CytomX Therapeutics, Inc.. Status: granted. Granted Nov 2, 2021. Expires Oct 28, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 45
- CPC classes
- A61P, A61P35/00
More from CytomX Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428470
Compositions containing activatable antibodies
granted -
US 12139543
Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR
granted -
US 12049505
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
granted -
US 11992528
Compositions and methods for conjugating activatable antibodies
granted -
US 11952427
Anti-CD40 antibodies and uses thereof
granted -
US 11890354
Activatable antibodies that bind epidermal growth factor receptor and methods thereof
granted -
US 11884746
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
granted -
US 11867695
Compositions and methods for detecting protease activity in biological systems
granted
Frequently asked questions
What is US patent 11161906?
US 11161906 (Multispecific antibodies, multispecific activatable antibodies and methods of using the same) is held by CytomX Therapeutics, Inc.. Status: granted. Granted Nov 2, 2021. Expires Oct 28, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11161906?
CytomX Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 62 pharmaceutical patents for this assignee.
When does US 11161906 expire?
Our index shows an expiration date of Oct 28, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.